CNBC

Euthymics Completes Enrollment in TRIADE, Its Advanced Trial of Amitifadine for Major Depressive Disorder

—TRIADE Designed to Address Excessive Placebo Response, a Prime Cause of Depression Trial Failure— —Trial Further Evaluates Amitifadine, Euthymics’ Proprietary Serotonin-Preferring Triple— CAMBRIDGE, ...
FierceBiotech

Euthymics Bioscience, Inc. Closes $24 Million Series A Financing and Completes Acquisition of DOV Pharmaceutical

--Company Will Develop a Novel Triple Reuptake Inhibitor Antidepressant for the Largest Single Segment of Patients with Major Depression-- CAMBRIDGE, Mass., Jul 22, 2010 (BUSINESS WIRE) -- --Euthymics ...
FiercePharma

Euthymics Bioscience, Inc. Presents Data That Support Advancing EB-1020 into Clinical Trials for Adult ADHD

CAMBRIDGE, Mass. & WAIKOLOA, Hawaii--(BUSINESS WIRE)-- Euthymics Bioscience, Inc. today announced that it has presented preclinical data demonstrating that EB-1020, a next-generation product candidate ...
GEN

Euthymics Bioscience Raises Series A Financing to $28M

Funding will accelerate preclinical development of firm’s therapeutic candidate for ADHD. Euthymics Bioscience added $4 million to the $24 million Series A financing it closed last June. The ...
FierceBiotech

Euthymics Bioscience Initiates Triade Trial for Major Depression

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Euthymics Bioscience, Inc. today announced the initiation of an advanced clinical study of its lead product candidate EB-1010 for the treatment of major depressive ...
The Business Journals

Euthymics says potential depression drug has promise at higher doses

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The good news to come out of a mid-stage clinical trial of ...
GEN

Euthymics Raises $24M to Progress Phase II/III-Stage Antidepressant

Firm believes triple-acting drug will benefit patients who do not respond to current SSRIs. Euthymics Bioscience raised $24 million in a Series A financing round led by Novartis Venture Funds and ...
Wall Street Journal

Euthymics Spinout Neurovance Picks Up $7M for ADHD Clinical Trials

Venture-backed neuroscience drug-maker Euthymics Bioscience Inc. has created a spinout, Neurovance Inc., that has raised $7 million in Series A-1 financing to develop a treatment for adults with ...
EurekAlert!

Euthymics presents phase II data for EB-1010 in major depression at ACNP annual meeting

Euthymics Bioscience, Inc. today will present Phase II clinical data demonstrating that its lead product candidate EB-1010, a next-generation antidepressant, is effective for treating major depressive ...
The Business Journals

Euthymics Bioscience appoints management team

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Euthymics Bioscience Inc. has made three appointments to ...
FiercePharma

Euthymics Completes Enrollment in TRIADE, Its Advanced Trial of Amitifadine for Major Depressive Disorder

Euthymics Bioscience, Inc.Anthony A. McKinney, 617-758-0300orMedia:Initiate PRJennifer Anderson (New York), 646-237-6926orStephen Gendel (Los Angeles), 310-878-4652 Euthymics Bioscience, Inc. today ...